Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;57 Suppl 19(Suppl 19):46-50.
doi: 10.1590/S0036-46652015000700009.

CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE

Flavio Queiroz-Telles  1
Affiliations
Review

CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE

Flavio Queiroz-Telles. Rev Inst Med Trop Sao Paulo. 2015 Sep.

Abstract
in English, Portuguese

Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM require long term therapy with systemic antifungals, sometimes associated with physical methods. Unlike other neglected endemic mycoses, comparative clinical trials have not been performed for this disease. Nowadays, therapy is based on a few open trials and on expert opinion. Itraconazole either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been successfully employed in combination with antifungals in patients presenting with CBM. In the present revision the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient's outcome.

Cromoblastomicose (CMB) é uma infecção fúngica crônica da pele e tecido subcutâneo causada pela inoculação transcutânea traumática de um grupo específico de fungos dermatiáceos que ocorrem principalmente em zonas tropicais e subtropicais do mundo. Quando não são diagnosticados nas fases iniciais, pacientes com CBM necessitam de tratamentos prolongados com antifúngicos sistêmicos, por vezes associados a métodos físicos. Diferentemente de outras micoses endêmicas negligenciadas, não foram realizados ensaios clínicos comparativos para esta doença. Atualmente a terapia é baseada em alguns poucos ensaios abertos e em opiniões de especialistas. Itraconazol é amplamente utilizado como monoterapia ou em associação com outras drogas, ou com métodos físicos. Recentemente, a terapia fotodinâmica foi empregada com sucesso combinada a antifúngicos em pacientes com CBM. Neste manuscrito as opções terapêuticas mais utilizadas contra CBM foram revistas, assim como os diversos fatores que podem influenciar a evolução dos pacientes

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. - Severe and recalcitrant clinical form of chromoblastomycosis.
Fig. 2
Fig. 2. - Clinical and microbiological aspects of chromoblastomycosis: The etiologic agent is easily found in the "black dot" lesion covered area (circled) A. Muriform cells are pathognomonic for this disease. They are observed either on wet mount (B) or in histologic sections. Fonsecaea pedrosoi is one of the prevalent agents in humid areas. Figures C and D depicts its macro and micromorphology aspects.
Fig. 3
Fig. 3. - Geographic distribution of chromoblastomycosis according to reported cases. (Courtesy of Dr Daniel Wagner dos Santos, University of Sao Paulo, Brazil).
Fig. 4
Fig. 4. Babassu (Orbignya phalerata) nutcracker woman in the State of Maranhao, Brazil. (Courtesy of Professor Conceição Pedroso, Federal University of Maranhao, Brazil).
Fig. 5
Fig. 5. - Lesions of chromoblastomycosis may depict clinical polymorphism end elicit several differential diagnoses. The initial lesion of chromoblastomycosis (1A), may evolve to five main clinical types: nodular lesions on the lower leg (1B), verrucous lesion of the foot (1C), scar lesions on the knee and lower leg (1D), plaque lesion on the buttocks (1E), tumoral (cauliflower) lesions on the foot (1G) and mixed lesions composed by plaque, nodular and verrucous lesions involving the lower limb (1H).
See this image and copyright information in PMC

References

    1. AL-DOORY Y. Di Salvo AF. Occupational mycoses. Philadelphia: Lea & Febiger; 1983. Chromomycosis; pp. 95–121.
    1. Antonello VS, Appel da Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo. 2010;52:329–331. - PubMed
    1. Attapattu MC. Chromoblastomycosis: a clinical and mycological study of 71 cases from Sri Lanka. Mycopathologia. 1997;137:145–151. - PubMed
    1. Avelar-Pires C, Simoes-Quaresma JA, Moraes de Macedo GM, Brasil-Xavier M, Cardoso de Brito A. Revisiting the clinical and histopathological aspects of patients with chromoblastomycosis from the Brazilian Amazon region. Arch Med Res. 2013;44:302–306. - PubMed
    1. Bolzinger T, Pradinaud R, Sainte-Marie D, Dupont B, Chwetzoff E. Traitement de quatre cas de chromomycose àFonsecaea pedrosoipar l'association 5-fluorocytosine-itraconazole. Nouv Dermatol. 1991;10:462–466.

MeSH terms